Pillar Biosciences Presents New Clinical Validation Data Confirming the Accuracy of its oncoReveal™ Dx Lung & Colon Cancer Assay in Detecting Clinically Relevant Variants

Pillar Biosciences Presents New Clinical Validation Data Confirming the Accuracy of its oncoReveal™ Dx Lung & Colon Cancer Assay in Detecting Clinically Relevant Variants April 11, 2022 Home  >  Resources  >  Press Release  > Pillar Biosciences Presents New Clinical Validation Data Confirming the Accuracy of its oncoReveal™ Dx Lung & Colon Cancer Assay in Detecting Clinically Relevant Variants – Laboratory and software validation testing determined ability to accurately identify key companion diagnostic targets within KRAS and EGFR genes, and specify associated approved therapy – These data, plus three additional studies, presented at the 2022 American Association for Cancer Research (AACR) […]

Pillar Biosciences Presents New Clinical Validation Data Confirming the Accuracy of its oncoReveal™ Dx Lung & Colon Cancer Assay in Detecting Clinically Relevant Variants Read more »